非特异性免疫疗法在支气管哮喘治疗中的应用进展(4)
[7]Pelaia G，Canonica GW，Matucci A，et al.Targeted therapy in severe asthma today：focus on immunoglobulin E[J].Drug Des Devel Ther，2017(11)：1979-1987.
[8]Minami D，Kayatani H，Sato K，et al.Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab[J].Respirol Case Rep，2019，7(1)：e00388.
[9]Corren J，Kavati A，Ortiz B，et al.Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma：A systematic literature review[J].Allergy Asthma Proc，2017，38(4)：250-263.
, 百拇医药
[10]王刚，王曾礼.哮喘发病机制中IgE调控及重组人抗IgE单克隆抗体的應用[J].中华结核与呼吸杂志，2003，26(7)：427-430.
[11]Pilon D，Kavati A，Ortiz B，et al.Asthma control，lung function，symptoms，and corticosteroid sparing after omalizumab？initiation in patients with allergic asthma[J].Allergy Asthma Proc，2018，39(2)：127-135.
[12]Di DB，Fiorino I，Taurino M，et al.Long-term"real-life"safety of omalizumab in patients with severe uncontrolled asthma：A nine-year study[J].Respiratory Medicine，2017(130)：55.
, 百拇医药
[13]Korn S，Thielen A，Seyfried S，et al.Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany[J].Respiratory Medicine，2009，103(11)：1725-1731.
[14]Grimaldi-Bensouda L，Zureik M，Aubier M，et al.Does omalizumab make a difference to the real-life treatment of asthma exacerbations？Results from a large cohort of patients with severe uncontrolled asthma[J].Chest，2013，143(2)：398-405.
[15]Jiang XG，Yang XD，Lv Z，et al.Elevated serum levels of TNF-α，IL-8，and ECP can be involved in the development and progression of bronchial asthma[J].Asthma，2018，55(2)：111-118.
, 百拇医药
[16]Brown SD.Brown LA.Stephenson S，et al.Characterization of a high TNF-α phenotype in children with moderate-to-severe asthma[J].J Allergy Clin Immunol，2015，135(6)：1651-1654.
[17]Taillé C，Poulet C，Marchand-Adam S，et al.Monoclonal Anti-TNF-αAntibodies for Severe Steroid-Dependent Asthma：A Case Series[J].Open Respir Med J，2013(7)： 21-25.
[18]Huang H，Nie W，Qian J，et al.Effects of TNF-α polymorphisms on asthma risk：a systematic review and meta-analysis[J].Investig Allergol Clin Immunol，2014，24(6)：406-417.
, 百拇医药
[19]Menzella F，Lusuardi M，Galeone C，et al.Tailored therapy for severe asthma[J].Multidiscip Respir Med，2015，10(1)：1-8.
[20]Patel SS，Casale TB，Cardet JC.Biological therapies for eosinophilic asthma[J].Expert Opin Biol Ther，2018，18(7)：747-754. [21]Barnes PJ.Targeting cytokines to treat asthma and chronic obstructive pulmonary disease[J].Nat Rev Immunol，2018，18(7)：454-466., http://www.100md.com(王晓燕 梁萍 董艳婷)
[8]Minami D，Kayatani H，Sato K，et al.Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab[J].Respirol Case Rep，2019，7(1)：e00388.
[9]Corren J，Kavati A，Ortiz B，et al.Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma：A systematic literature review[J].Allergy Asthma Proc，2017，38(4)：250-263.
, 百拇医药
[10]王刚，王曾礼.哮喘发病机制中IgE调控及重组人抗IgE单克隆抗体的應用[J].中华结核与呼吸杂志，2003，26(7)：427-430.
[11]Pilon D，Kavati A，Ortiz B，et al.Asthma control，lung function，symptoms，and corticosteroid sparing after omalizumab？initiation in patients with allergic asthma[J].Allergy Asthma Proc，2018，39(2)：127-135.
[12]Di DB，Fiorino I，Taurino M，et al.Long-term"real-life"safety of omalizumab in patients with severe uncontrolled asthma：A nine-year study[J].Respiratory Medicine，2017(130)：55.
, 百拇医药
[13]Korn S，Thielen A，Seyfried S，et al.Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany[J].Respiratory Medicine，2009，103(11)：1725-1731.
[14]Grimaldi-Bensouda L，Zureik M，Aubier M，et al.Does omalizumab make a difference to the real-life treatment of asthma exacerbations？Results from a large cohort of patients with severe uncontrolled asthma[J].Chest，2013，143(2)：398-405.
[15]Jiang XG，Yang XD，Lv Z，et al.Elevated serum levels of TNF-α，IL-8，and ECP can be involved in the development and progression of bronchial asthma[J].Asthma，2018，55(2)：111-118.
, 百拇医药
[16]Brown SD.Brown LA.Stephenson S，et al.Characterization of a high TNF-α phenotype in children with moderate-to-severe asthma[J].J Allergy Clin Immunol，2015，135(6)：1651-1654.
[17]Taillé C，Poulet C，Marchand-Adam S，et al.Monoclonal Anti-TNF-αAntibodies for Severe Steroid-Dependent Asthma：A Case Series[J].Open Respir Med J，2013(7)： 21-25.
[18]Huang H，Nie W，Qian J，et al.Effects of TNF-α polymorphisms on asthma risk：a systematic review and meta-analysis[J].Investig Allergol Clin Immunol，2014，24(6)：406-417.
, 百拇医药
[19]Menzella F，Lusuardi M，Galeone C，et al.Tailored therapy for severe asthma[J].Multidiscip Respir Med，2015，10(1)：1-8.
[20]Patel SS，Casale TB，Cardet JC.Biological therapies for eosinophilic asthma[J].Expert Opin Biol Ther，2018，18(7)：747-754. [21]Barnes PJ.Targeting cytokines to treat asthma and chronic obstructive pulmonary disease[J].Nat Rev Immunol，2018，18(7)：454-466., http://www.100md.com(王晓燕 梁萍 董艳婷)